Cartesian Therapeutics Inc. (RNAC) support and resistance · P/E 2.1, rev $38.9M
Cartesian Therapeutics Inc. (RNAC) is a biotechnology company listed on US.
This page maps Cartesian Therapeutics Inc. (RNAC) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported RNAC revenue for 2024-12-31 was $38.9M. Net income was -$77.4M. Revenue was up 49.6% from 2023-12-31 to 2024-12-31. RNAC currently screens at market cap $290.9M and trailing P/E 2.1.
RNAC currently screens at market cap $290.9M and trailing P/E 2.1. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new RNAC 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the RNAC quote page for the session range and the stock page for the full model.
Not investment advice.